CD20 negative

P1, N=18, Recruiting, Chongqing Precision Biotech Co., Ltd

P1, N=23, Completed, Kite Pharma Inc. | Active, not recruiting --> Completed

P2, N=33, Recruiting, University of Washington | Not yet recruiting --> Recruiting

CD20-negative large B-cell lymphomas exhibit aggressive behavior and are ineligible for rituximab-containing therapy...In conclusion, CD79B and CD19 were variably expressed in CD20-negative large B-cell lymphomas, but lower in de novo DLBCL, and especially in plasmablastic lymphoma. Programmed cell death protein 1/programmed death-ligand one inhibitors may represent a treatment option.

P1, N=12, Completed, Institute of Hematology & Blood Diseases Hospital, China | Unknown status --> Completed

P1/2, N=30, Recruiting, Suzhou Immunofoco Biotechnology Co., Ltd

We extended this strategy to develop a trispecific CAR T platform co-expressing a secretable CD3/CD22 bispecific engager, achieving potent tumor eradication even in CD19/CD20-negative malignancies demonstrates efficacy across patient-derived leukemia samples and solid tumor models. Together, our study introduces a next-generation AI-guided CAR T strategy that integrates structure-based optimization and intracellular modulation to improve persistence, broaden antigen coverage, and ensure durable therapeutic efficacy.

The patient was treated with bendamustine-based chemotherapy and corticosteroids, with marked clinical and radiological improvement. This case emphasizes the importance of considering hematologic malignancies in the differential diagnosis of breast lesions to avoid unnecessary surgical management and ensure appropriate systemic therapy.

Syk-NFκB signaling promotes FcεRγI expression in hBBζ CARTs, and CAR-TCR interactions potentiate NFκB signaling to upregulate FcεRγI and enhance CART function. These studies identify a potent therapeutic subset of innate-like canine CARTs induced by hBBζ signaling, which holds potential to improve both canine and human CART therapy.

P1, N=40, Recruiting, University Health Network, Toronto | Trial completion date: Jun 2027 --> Sep 2027 | Trial primary completion date: Jun 2025 --> Sep 2027

Additionally, advanced disease outcomes may improve with the use of targeted agents, such as proteasome inhibitors and anti-CD38 monoclonal antibodies, when added to combination chemotherapy. Participation in clinical trials and multi-institutional collaboration will be essential to continue improving patient outcomes with PBL.

This case highlights the diagnostic limitation of endoscopic biopsy following rituximab therapy. Therefore, clinicians should be cautious in relying solely on endoscopic findings and remain open to surgical intervention to achieve a timely and accurate diagnosis.